The authors discuss the nonhypoglycemic effects of the thiazolidinediones, with an emphasis on the potential of these drugs
to improve other components of the insulin resistance syndrome, such as dyslipidemia, hypertension, and impaired fibrinolysis.
They also describe the thiazolidinediones' effects in other insulin-resistant states, such as the polycystic ovary syndrome;
examine their effects on body weight and composition; and draw attention to other potential effects currently being investigated.